TICKERNERD
Menu
PHIOPHIOHealthcare · Biotechnology

PHIO Stock Forecast: Phio Pharmaceuticals Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.18
−2.48% on the day

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. hold a median 12-month price target of $14 — +1086.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$13.7M
Ticker Nerd rank
18 / 100
Median analyst target
$14
Analysts covering
1
Total return, dividends reinvested
1W
+8.3%
1M
+4.4%
YTD
+12.4%
1Y
−43.0%
From 52W high
−52.4%
From 52W low
+37.7%
$0.86
$2.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phio Pharmaceuticals Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Volatility
62
Quality
45
Accruals
44
Revisions
33
Issuance
25
Growth
25
Value
15
Momentum
5

Size (91): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26PHIOHigh $14Median $14Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $14Median $14High $14

The green dot is the last close — the median target sits +1086.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Feb 2026HC Wainwright & Co.ReiteratesBuy$14
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
5 June 2025HC Wainwright & Co.AssumesBuy$14
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
6 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 June 2021HC Wainwright & Co.MaintainsBuy$4.00 → $6.00
25 Nov 2020HC Wainwright & Co.InitiatesBuy—
5 Aug 2020HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PHIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Phio Pharmaceuticals Corp. (PHIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−113.7%

Higher than 12% of US stocks

Return on assets
−65.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PHIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHIOPhio Pharmaceuticals Corp.$13.7M
18
LSTALisata Therapeutics, Inc.$14.0M
59
NRSNNeurosense Therapeutics Ltd.$14.2M
3
PASGPassage Bio, Inc.$14.3M
38
GTBPGT Biopharma, Inc.$13.0M
14
ICUSeastar Medical Holding Corp.$14.8M
24
INABIN8bio, Inc.$12.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phio Pharmaceuticals Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHIO news & analysis

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Newsfile Corp · 6 Aug 2026positive

Phio Pharmaceuticals reported its financial results for the quarter ended June 30, 2026, and provided a business update. The company highlighted strategic milestone advancements for its lead clinical candidate PH-762, including initiation of commercial scale API production, long-term non-clinical toxicology work, completion of Phase 1b pharmacology, and new intellectual property announcements.

Why it matters — A PHIO watcher would care because these milestones mark progress for its lead clinical candidate PH-762 toward commercialization-readiness and the expansion of its intellectual property position.

FAQ

Frequently asked questions about PHIO stock

What is the PHIO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHIO stock a buy right now?

Of the 1 analysts covering Phio Pharmaceuticals Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phio Pharmaceuticals Corp. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHIO?

As at 22 Aug 2026, Phio Pharmaceuticals Corp. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will PHIO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1086.4% from the last close, and Ticker Nerd's factor model ranks Phio Pharmaceuticals Corp. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHIO stock forecast for 2030?

No analyst covering Phio Pharmaceuticals Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.

How has PHIO stock performed over the past year?

Phio Pharmaceuticals Corp. returned -43.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phio Pharmaceuticals Corp. do?

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at treating cancer.

What is the latest news on PHIO?

The most recent item we track (Newsfile Corp, 6 Aug 2026): "Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update". Phio Pharmaceuticals reported its financial results for the quarter ended June 30, 2026, and provided a business update. The company highlighted strategic milestone advancements for its lead clinical candidate PH-762, including initiation of commercial scale API production, long-term non-clinical toxicology work, completion of Phase 1b pharmacology, and new intellectual property announcements.

Company

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at treating cancer. The company's primary goal is to leverage its proprietary self-delivering RNAi (sd-rxRNA) technology, designed to advance immune responses against cancer by enhancing the activation and persistence of immune cells. This innovative platform is central to its efforts in creating treatments that improve the efficacy of existing cancer therapies or standalone applications. Phio Pharmaceuticals Corp. is actively engaged in research and development, and its initiatives predominantly impact the biotechnology and healthcare sectors. Based in Marlborough, Massachusetts, the company plays a significant role in the ongoing efforts to find novel solutions to combat challenging cancer types, positioning itself as a key player in immunotherapy advancements. By collaborating with other biotech firms and healthcare institutions, Phio Pharmaceuticals aims to bring effective, trailblazing medicines to market, which could significantly alter the landscape of cancer treatment.

CEO Mr. Robert J. Bitterman · 6 employees · United States · https://phiopharma.com